Quick Answer
Inhibrx Biosciences, Inc. reported Total Revenue of $1.30 million for the year ending 2025.
- Inhibrx Biosciences, Inc. showed an increase of +550.0% in Total Revenue from 2024 to 2025.
- This data is from Inhibrx Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $30.0 thousand | Q3 2023: $119.0 thousand | Q2 2024: $100.0 thousand | Q3 2024: $0.00 | Q2 2025: $1.30 million | Q3 2025: $0.00.
- Over the full 3 years of available data (2023 to 2025), Inhibrx Biosciences, Inc.'s Total Revenue has declined by 27.8%.
- Historical annual values: Fiscal year 2025: $1.30 million | Fiscal year 2024: $200.0 thousand | Fiscal year 2023: $1.80 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: